Brief: Pharnext Announces Data From Open-Label Phase 3 Extension Study Of PXT3003

Pharnext SCA

06/01/2020 18:07

Jan 6 (Reuters) - PHARNEXT SA  PHARN.PA :
    * PHARNEXT ANNOUNCES ENCOURAGING DATA FROM OPEN-LABEL PHASE
3
EXTENSION STUDY OF PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE
1A (CMT1A)
    * RESULTS SUGGEST SUSTAINED SAFETY AND EFFICACY OF PXT3003
IN
CMT1A PATIENTS AFTER 25 MONTHS OF TOTAL TRIAL TIME
    * CMT1A PATIENTS SHOWED IMPROVEMENT OR STABILIZATION OF
DISEASE AS
MEASURED BY OVERALL NEUROPATHY LIMITATIONS SCALE DURING
OPEN-LABEL PHASE 3 EXTENSION STUDY
    * EXPECTS TO KEEP PATIENTS CURRENTLY ENROLLED IN PHASE 3
EXTENSION
STUDY ON TREATMENT UNTIL PXT3003 COMMERCIALLY AVAILABLE

Source text for Eikon:  ID:nEQ69TBLra 
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))